Events

With more than 2,900 life sciences organisations employing one in every 60 Australians, the sector continues to grow as a pillar of the nation’s future innovation economy. This week’s announcements, from expanding trade facilitation to forging international partnerships and welcoming record global delegates, underscore Australia’s ambition to play a leading role in the global life sciences landscape.

Telix Pharmaceuticals (ASX:TLX) has dosed the first patient in its Phase 1 clinical trial evaluating TLX090 (¹⁵³Samarium (Sm)-DOTMP), a next-generation therapeutic radiopharmaceutical being developed to treat pain associated with metastatic bone disease.

Australia’s premier life sciences investment forum opened in Melbourne earlier this week, bringing together investors, innovators and global partners to explore one of the most dynamic periods in the nation’s biotechnology and medical technology sectors.

Starpharma Holdings (ASX:SPL) has received an upfront payment of US$5.5 million (A$8.5 million) from Genentech, a member of the Roche Group, marking the formal commencement of their recently announced license agreement focused on developing dendrimer-drug conjugates for selected oncology targets.

Island Pharmaceuticals (ASX:ILA) has confirmed that the US Food and Drug Administration will provide formal feedback on its antiviral candidate Galidesivir by 12 November 202, despite recent government shutdowns in the United States.

Noxopharm (ASX:NOX) has secured a significant milestone in the development of its Sofra technology platform, announcing the granting of its first patent by the United States Patent and Trademark Office.

4DMedical (ASX:4DX) has taken a significant step in the commercial rollout of its flagship CT:VQ technology. It announced that Stanford University has become the first US Academic Medical Centre...

ImpediMed (ASX:IPD) has signalled a sharper focus on sales execution and market expansion following a strong finish to the financial year 2025, underpinned by record contract value, growing reimbursement coverage in the US, and advancing opportunities in lymphoedema, body composition and heart failure.

IDT Australia (ASX:IDT) has announced a strategic realignment to sharpen its operational focus, deliver $1 million in annualised cost savings from financial year 2026, and position the business for more sustainable growth.

Clarity Pharmaceuticals (ASX:CU6) has highlighted new clinical and commercial data supporting its proprietary copper-based theranostics platform, underscoring its potential to redefine imaging and therapy for prostate cancer.

PYC Therapeutics (ASX:PYC) has taken a significant step forward in its goal to deliver the first treatment for Autosomal Dominant Optic Atrophy, announcing the initiation of a global repeat-dose Phase 1b clinical study of its investigational RNA therapy, PYC-001.

Neuren Pharmaceuticals (ASX:NEU) has received Fast Track designation from the US Food and Drug Administration for its investigational therapy NNZ-2591 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder with no approved therapies.